Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

November 18, 2022

Study Completion Date

August 14, 2024

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal Large B-Cell Lymphoma
Interventions
DRUG

Copanlisib Hydrochloride

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (15)

27157

Wake Forest University Health Sciences, Winston-Salem

35233

University of Alabama at Birmingham Cancer Center, Birmingham

40536

University of Kentucky/Markey Cancer Center, Lexington

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic in Rochester, Rochester

64108

University Health Truman Medical Center, Kansas City

66061

The University of Kansas Cancer Center - Olathe, Olathe

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Hospital-Westwood Cancer Center, Westwood

66606

University of Kansas Health System Saint Francis Campus, Topeka

66762

Ascension Via Christi - Pittsburg, Pittsburg

67401

Salina Regional Health Center, Salina

67601

HaysMed, Hays

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

03756

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03484819 - Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter